Skip to main content

Table 3 Persistence of hemagglutination-inhibition antibody geometric mean titers with 95% CI in the per-protocol immunogenicity cohort

From: Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults

Month

6

6 + 21 days

12

12 + 21 days

18

24

30

36

36 + 21 days

42

48

Boosted at Month 6

Primary strain

N = 256

N = 256

N = 228

–

N = 216

N = 200

N = 200

N = 208

–

N = 201

N = 194

 

19.1

397.4

76.1

 

43.7

32.2

27.5

24.3

 

20.1

22.9

 

(16.5, 22.5)

(342.5, 461.0)

(62.5, 92.7)

 

(36.7, 52.0)

(27.3, 37.9)

(23.6, 32.2)

(20.6, 28.6)

 

(17.3, 23.5)

(19.6, 26.9)

Booster strain

N = 256

N = 256

N = 228

–

N = 216

N = 200

N = 200

N = 208

–

N = 201

N = 194

 

6.4

321.3

46.9

 

4.9

22.2

22.1

24.5

 

17.8

19.5

 

(6, 6.9)

(274.3, 376.2)

(38.3, 57.4)

 

(45.6, 66.1)

(18.8, 26.0)

(18.8, 26.0)

(20.6, 29.1)

 

(15.2, 20.9)

(16.6, 23.0)

Boosted at Month 12

Primary strain

N = 665

–

N = 178

N = 184

N = 182

N = 177

N = 177

N = 178

–

N = 176

N = 170

 

18.5

 

11.8

649.7

145.2

68.5

53.0

51.2

 

39.0

41.8

 

(5, 5.1)

 

(10.0, 14.0)

(549.6, 768.1)

(118.1, 178.6)

(55.9, 83.9)

(44.6, 63.1)

(42.3, 62.0)

 

(32.6, 46.6)

(34.7, 50.4)

Booster strain

N = 665

–

N = 178

N = 184

N = 182

N = 177

N = 177

N = 178

–

N = 176

N = 170

 

6.3

 

6.2

338

190.7

51.3

45.5

52.4

 

37

37.9

 

(6, 6.5)

 

(5.7, 6.7)

(280, 407.2)

(154.3, 235.7)

(44.6, 63.1)

(37.2, 55.8)

(42.3, 65.1)

 

(30.3, 45.2)

(30.9, 46.4)

Boosted at Month 36

Primary strain

–

–

N = 365

–

N = 429

N = 411

N = 413

N = 387

N = 379

N = 378

N = 367

   

11.3

 

10.2

10.8

10.7

10.5

653.1

225.4

165.1

   

(10.1, 12.6)

 

(9.3, 11.3)

(9.8, 11.8)

(9.7, 11.7)

(9.5, 11.6)

(604.3–705.9)

(205, 247.9)

(149.8, 181.9)

Booster strain

–

–

N = 364

–

N = 429

N = 411

N = 413

N = 387

N = 379

N = 378

N = 367

   

6.2

 

9.6

6.0

6.3

7.0

877.5

263.5

171.3

   

(5.8, 6.7)

 

(8.7, 10.6)

(5.7, 6.3)

(6.0, 6.6)

(6.5, 7.6)

(809.1, 951.6)

(238.3, 291.3)

(155.0, 189.3)

  1. CI, confidence interval; N, number of subjects in group; Responses are based on per-protocol immunogenicity cohort before vaccination and at vaccination + 21 days; responses at time-points post-vaccination are based on per-protocol immunogenicity persistence cohorts; Primary vaccine strain, H5N1/A/Vietnam/1194/2004; booster strain, H5N1/A/Indonesia/5/2005.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us